Risperdal settlement to cost J&J $181 millionRisperdal to providers treating patients with Alzheimer's and dementia, Reuters reported. The drug, which is intended to treat schizophrenia, is not approved for these conditions.
Bethesda, MD-based MidCap Financial has just inked a sizable loan with the nation's largest skilled nursing operator.
A trade group representing Maryland long-term care facilities is partnering up with a vendor as part of a turnover-reduction effort.
Consumer Advocate has announced its top medical alert systems.